Drugs / BMS-986166
last change Oct 2022 re-read 2 minutes ago

BMS-986166

Small molecule

Developed for
atopic eczema
Investigated by
Bristol-Myers Squibb

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT05409157 Jun → Oct 2022 Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT04934696 Aug 2021 → Jan 2022 Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT04956627 Jul 2021 → Apr 2022 Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT04965402 Jul 2021 → Feb 2022 Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT03038711 Feb → Aug 2017 ulcerative colitis Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT02790125 Jul 2016 → Nov 2017 Bristol-Myers Squibb Completed No outcome recorded
Phase 21 trial
Phase 2 NCT05014438 Aug 2021 → Aug 2022 atopic eczema Bristol-Myers Squibb Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as BMS-986166 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04934696
6

NCT05014438

NCT02790125

NCT03038711

NCT04965402

NCT04956627

NCT05409157

Known as BMS-986166 HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4649457
Known as BMS-986166-04 ChEMBL registry synonym — accepted as the source's own label CHEMBL4649457
Modality Small molecule CHEMBL4649457
Route Oral “Single oral dose of solution as specified” NCT02790125